Page 27 - Read Online

Arroyo Seguí et al. J Transl Genet Genom 2020;4:263-77 I http://dx.doi.org/10.20517/jtgg.2020.35 Page 277

42. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation
modulates substance dependence risk. Mol Psychiatry 2008;13:531-43.
43. Beer B, Erb R, Pavlic M, Ulmer H, Giacomuzzi S, et al. Association of polymorphisms in pharmacogenetic candidate genes (OPRD1,
GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One 2013;8:e75359.
44. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of
liver health: a randomized trial. Drug Alcohol Depend 2013;128:71-6.
45. Blanco F, Muriel C, Labrador J, Gonzalez-Porras JR, Gonzalez-Sarmiento R, et al. Influence of UGT2B7, CYP3A4, and OPRM1 gene
polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization. Pain
Pract 2016;16:842-9.
46. Muriel J, Margarit C, Planelles B, Serralta MJ, Puga C, et al. OPRM1 influence on and effectiveness of an individualized treatment plan
for prescription opioid use disorder patients. Ann N Y Acad Sci 2018;1425:82-93.
47. Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, et al. Association of OPRD1 polymorphisms with heroin dependence in a large
case-control series. Addict Biol 2014;19:111-21.
48. Crist RC, Phillips KA, Furnari MA, Moran LM, Doyle GA, et al. Replication of the pharmacogenetic effect of rs678849 on buprenorphine
efficacy in African-Americans with opioid use disorder. Pharmacogenomics J 2019;19:260-8.
49. Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, et al. Genetic variation in OPRD1 and the response to treatment for opioid
dependence with buprenorphine in European-American females. Pharmacogenomics J 2014;14:303-8.
50. Moody DE, Fang WB, Morrison J, McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug
Alcohol Depend 2011;118:479-83.
51. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J
Psychiatry 1999;156:842-8.
52. Unger A, Jung E, Winklbaur B, Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis
2010;29:217-30.
53. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA
2004;291:1887-96.
54. Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after
treatment for opiate addiction. Addiction 1998;93:73-92.
55. Gerra G, Somaini L, Leonardi C, Cortese E, Maremmani I, et al. Association between gene variants and response to buprenorphine
maintenance treatment. Psychiatry Res 2014;215:202-7.
56. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci 2013;14:609-25.
57. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology
2010;210:121-35.
58. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, et al. The D2 dopamine receptor gene as a determinant of reward deficiency
syndrome. J R Soc Med 1996;89:396-400.
59. Lawford BR, Young RMD, Noble EP, Sargent J, Rowell J, et al. The D2 dopamine receptor A1 allele and opioid dependence: association
with heroin use and response to methadone treatment. Am J Med Genet 2000;96:592-8.
60. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine
maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 2006;141:323-31.
61. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug
Metab Dispos 2005;33:689-95.
62. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug
Metab Dispos 1984;12:577-81.
63. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of
genetic variation. Pharmacol Ther 2013;138:103-41.
64. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms
to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver
microsomes. Drug Metab Dispos 2010;38:40-5.
65. Ettienne EB, Chapman E, Maneno M, Ofoegbu A, Wilson B, et al. Pharmacogenomics-guided policy in opioid use disorder (OUD)
management: an ethnically-diverse case-based approach. Addict Behav Rep 2017;6:8-14.
66. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, et al. Identification and characterization of CYP3A4* 20, a novel
rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006;79:339-49.
67. Ettienne EB, Ofoegbu A, Maneno MK, Briggs J, Ezeude G, et al. Pharmacogenomics and opioid use disorder: clinical decision support in
an African American cohort. J Natl Med Assoc 2019;111:674-81.
68. Muriel J, Margarit C, Barrachina J, Ballester P, Flor A, et al. Pharmacogenetics and prediction of adverse events in prescription opioid use
disorder patients. Basic Clin Pharmacol Toxicol 2019;124:439-48.
69. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al. Pharmacogenomics knowledge for personalized medicine. Clin
Pharmacol Ther 2012;92:414-7.